Our TCR-T technique is featured by using the patented artificial antigen presentation system to prepare tumor specific CTL cells. The sequences coding for TCRα and βsubunits are decoded and cloned from antigen peptide-Tetramer positive cells. The TCRα and β gene will then be inserted into retroviruses or lentiviruses derived vectors and transduced into peripheral blood derived T cells for high expression of antigen-specific TCR to become tumor-specific CTL clone (TCR-T) and to obtain potent tumor cell killing activity.
Currently, we are focused on target molecule NY-ESO-1 (New York esophageal squamous cell carcinoma 1), an important member of cancer-testis antigens (CTA) family. NY-ESO-1 can induce humoral immune response and activate CD4+ and CD8+ T-lymphocytes. NY-ESO-1 is widely expressed in a variety of tumor cells such as melanoma, esophageal cancer, bladder cancer, lung cancer and exhibits, thus far, strongest immunogenicity among all tumor-specific antigens. NY-ESO-1 has not been detected in normal tissues except in testicular tissue. Testis cells do not express MHC-I and MHC-II molecules, thereby escaping T cell attack via NY-ESO-1 target. This unique property makes NY-ESO-1 a hotspot in tumor immunotherapy research.
1. Maintaining the natural structure of TCR for proper interaction with cofactors, not only
maintains the strength of activation signal, but also ensures the control of activation
strength, and thus manifests safety
2. Efficient and specific system of TCR cloning and screening
3. Higher expression of specific TCR enables CTLto recognizie and kill tumor cells with more